Flow cytometry technology developer FlowMetric Life Sciences announced today that it launched a COVID-19 antibody test.
Doylestown, Pa.-based FlowMetric’s antibody test provides greater than 99% specificity and 99% sensitivity more than 14 days after COVID-19 symptoms appear, according to a news release.
The diagnostic is also touted as capable of differentiating an infection due to virus exposure vs. a vaccine response, while its detection of antibodies covers a wide, dynamic range. Additionally, it can identify antibodies for multiple SARS-CoV-2 proteins.
FlowMetric’s CLIA-certified laboratory offers capabilities for processing over 1,000 samples per day with results provided within 24-48 hours.
“The applications of this advanced, multiplexed assay are ideal for companies working on vaccine development or COVID-19 related therapeutics,” FlowMetric founder & CEO Renold Capocasale said in the release.